BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$88,881 | -$226,539 | -$247,116 | -$184,062 |
| Dep. & Amort. | $1,246 | $1,655 | $1,437 | $777 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $65,413 | $55,615 | $44,701 | $34,640 |
| Change in WC | -$87,282 | -$32,401 | -$58,945 | $8,124 |
| Other Non-Cash | $57,484 | $106,529 | $98,073 | -$1,636 |
| Operating Cash Flow | -$52,020 | -$95,141 | -$161,850 | -$142,157 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,124 | -$2,168 | -$1,351 | -$2,385 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$266,763 | -$514,407 | -$244,283 | -$10,012 |
| Inv. Sales/Matur. | $320,480 | $385,077 | $117,396 | $28,201 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $52,593 | -$131,498 | -$128,238 | $15,804 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$1,704 | $58,383 | $73,072 | $293,874 |
| Stock Issued | $34 | $342 | $190 | $50,060 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$4,091 | -$26,240 | $14,765 | $15,734 |
| Financing Cash Flow | -$5,761 | $32,485 | $88,027 | $359,668 |
| Forex Effect | -$936 | $362 | $566 | $71 |
| Net Chg. in Cash | -$6,124 | -$193,792 | -$201,495 | $233,386 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $112,447 | $306,239 | $507,734 | $274,348 |
| End Cash | $106,323 | $112,447 | $306,239 | $507,734 |
| Free Cash Flow | -$53,144 | -$97,309 | -$163,201 | -$144,542 |